CinCor Pharma Overview
Valuation check: CINC's P/E ratio is -20.46, below the sector sector average of 44.85.
Get informed when a big investor buys or sells
+ Follow-20.46
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
CinCor Pharma (CINC) currently reports a P/E ratio of -20.46. That is below the sector sector average of 44.85. Use the charts on this page to explore CinCor Pharma's P/E ratio history and peer comparisons.
CinCor Pharma's P/E ratio of -20.46 is lower than the its sector sector average of 44.85. That is roughly 145.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates CinCor Pharma's market price to a fundamental measure such as earnings, sales, or book value. At -20.46, CINC can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -20.46, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 44.85. From there, open related valuation or income-statement pages for CinCor Pharma, and consider following CINC for alerts when major investors trade the stock.
